NEW YORK (GenomeWeb) – Foundation Medicine and the Sarah Cannon Research Institute are collaborating to use genomic profiling as part of clinical trials, the organizations said today.

Under the partnership, researchers can use Foundation Medicine's FoundationOne assay for solid tumors, FoundationOne Heme for hematologic cancers, and FoundationACT for liquid biopsy analysis to identify patients eligible for Sarah Cannon's clinical studies.

Sarah Cannon will also integrate Foundation's decision support portal, called Interactive Cancer Explorer, across its network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.